These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Commentary on: Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism, by D. Williams, R. de Silva, D. Paviour, et al. (Brain-2004-01045.R1). Burn DJ Brain; 2005 Jun; 128(Pt 6):1235-6. PubMed ID: 15900030 [No Abstract] [Full Text] [Related]
31. Differentiating between common PSP phenotypes using structural MRI: a machine learning study. Quattrone A; Sarica A; Buonocore J; Morelli M; Bianco MG; Calomino C; Aracri F; De Maria M; Vescio B; Vaccaro MG; Quattrone A J Neurol; 2023 Nov; 270(11):5502-5515. PubMed ID: 37507502 [TBL] [Abstract][Full Text] [Related]
32. Neuropsychological assessment could distinguish among different clinical phenotypes of progressive supranuclear palsy: A Machine Learning approach. Vaccaro MG; Sarica A; Quattrone A; Chiriaco C; Salsone M; Morelli M; Quattrone A J Neuropsychol; 2021 Sep; 15(3):301-318. PubMed ID: 33231380 [TBL] [Abstract][Full Text] [Related]
33. The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. Seckin ZI; Duffy JR; Strand EA; Clark HM; Utianski RL; Machulda MM; Botha H; Ali F; Thu Pham NT; Lowe VJ; Whitwell JL; Josephs KA Parkinsonism Relat Disord; 2020 Dec; 81():34-40. PubMed ID: 33045651 [TBL] [Abstract][Full Text] [Related]
34. Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome. Ahn JH; Kim M; Kim JS; Youn J; Jang W; Oh E; Lee PH; Koh SB; Ahn TB; Cho JW Parkinsonism Relat Disord; 2019 Sep; 66():80-86. PubMed ID: 31307918 [TBL] [Abstract][Full Text] [Related]
35. Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. Nigro S; Antonini A; Vaillancourt DE; Seppi K; Ceravolo R; Strafella AP; Augimeri A; Quattrone A; Morelli M; Weis L; Fiorenzato E; Biundo R; Burciu RG; Krismer F; McFarland NR; Mueller C; Gizewski ER; Cosottini M; Del Prete E; Mazzucchi S; Quattrone A Mov Disord; 2020 Jun; 35(6):976-983. PubMed ID: 32092195 [TBL] [Abstract][Full Text] [Related]
36. Are PSP patients included in clinical trials representative of the general PSP population? Mariani LL; Guimarães-Costa R; Grabli D; Le Toullec B; Cormier-Dequaire F; Degos B; Dubois B; Vidailhet M; Lacomblez L; Corvol JC Parkinsonism Relat Disord; 2019 Sep; 66():202-206. PubMed ID: 31303434 [TBL] [Abstract][Full Text] [Related]
37. Phenotypic Spectrum of Progressive Supranuclear Palsy: Clinical Study and Apolipoprotein E Effect. Nasri A; Sghaier I; Neji A; Gharbi A; Abida Y; Mrabet S; Gargouri A; Djebara MB; Kacem I; Gouider R J Mov Disord; 2024 Apr; 17(2):158-170. PubMed ID: 38290492 [TBL] [Abstract][Full Text] [Related]
39. The in vivo distribution of brain tissue loss in Richardson's syndrome and PSP-parkinsonism: a VBM-DARTEL study. Agosta F; Kostić VS; Galantucci S; Mesaros S; Svetel M; Pagani E; Stefanova E; Filippi M Eur J Neurosci; 2010 Aug; 32(4):640-7. PubMed ID: 20597976 [TBL] [Abstract][Full Text] [Related]
40. "Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism. Necpál J; Borsek M; Jeleňová B Neurol Sci; 2021 Dec; 42(12):4927-4936. PubMed ID: 34532773 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]